Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck - A Hellenic cooperative oncology group phase II study (Journal article)

Fountzilas, G./ Tolis, C./ Kalogera-Fountzila, A./ Misailidou, D./ Tsekeris, P./ Karina, M./ Nikolaou, A./ Samantas, E./ Makatsoris, T./ Athanassiou, E./ Skarlos, D./ Bamias, A./ Zamboglou, N./ Economopoulos, T./ Karanastassi, S./ Pavlidis, N./ Daniilidis, J.

The primary objective of this phase II study was to access the complete response (CR) rate to a new innovative induction regimen in patients with locally advanced head and neck cancer (LA-HNC). From October 2000 until October 2003 a total of 38 eligible patients (33 men and 5 women) entered the study. The large majority of them presented with a performance status of 0-1 and with clinical stage IV disease. Treatment consisted of three cycles of induction chemotherapy (IC) with paclitaxel 175 mg/m(2) in a 3-h infusion on d 1, leucovorin (LV) 200 mg/m(2) over 20 min immediately followed by FU 400 mg/m(2) bolus and then 600 mg/m(2) as a 24-h continuous infusion on d 1 and 2 and a cisplatin 75 mg/m(2) over 1-h infusion on d 2 every 3 wk. This was then followed by radiation (70 Gy) and weekly cisplatin 40 mg/m(2). After the completion of IC, 6/38 (16%) patients had CR. The CR rate was increased to 66% post-concomitant chemoradiotherapy (CCRT). Neutropenia (37.5%), pain (62%), nausea/vomiting (21%), and alopecia (79%) were the most frequent side effects during IC. The most pronounced toxicities during chemoradiotherapy were stomatitis (62.5%) and xerostomia (53%). Median time to progression was 11.0 mo and median survival 16.7 mo. One- and 2-yr survival rates were 73% and 38%, respectively. In conclusion, this novel induction regimen is active, is well tolerated, and can be successfully followed by CCRT with weekly cisplatin. CCRT should remain standard treatment for patients with LA-HNC. Novel induction combinations, such as that reported in the present study, should be evaluated in combination with CCRT only in the context of clinical trials.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών
Keywords: paclitaxel,chemotherapy,head and neck cancer,induction chemotherapy,radiation-therapy,randomized-trial,organ preservation,weekly carboplatin,cancer,radiotherapy,survival,radiochemotherapy,oxaliplatin
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/17413
ISSN: 1357-0560
Link: <Go to ISI>://000231533600007
http://link.springer.com/content/pdf/10.1385%2FMO%3A22%3A3%3A269.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Fountzilas-2005-Paclitaxel, cisplati.pdf91.33 kBAdobe PDFView/Open    Request a copy


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/17413
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.